Archives: “Therapeutic Development”

Tolebrutinib in nonrelapsing secondary progressive multiple sclerosis

https://www.coltonconsortium.org/publications/tolebrutinib-in-nonrelapsing-secondary-progressive-multiple-sclerosis/

Trajectory of beta cell function and insulin clearance in stage 2 type 1 diabetes: natural history and response to teplizumab

https://www.coltonconsortium.org/publications/trajectory-of-beta-cell-function-and-insulin-clearance-in-stage-2-type-1-diabetes-natural-history-and-response-to-teplizumab/

Transcriptomic profiling after B cell depletion reveals central and peripheral immune cell changes in multiple sclerosis

https://www.coltonconsortium.org/publications/transcriptomic-profiling-after-b-cell-depletion-reveals-central-and-peripheral-immune-cell-changes-in-multiple-sclerosis/

Transmembrane domain–driven PD-1 dimers mediate T cell inhibition

https://www.coltonconsortium.org/publications/transmembrane-domain-driven-pd-1-dimers-mediate-t-cell-inhibition/

Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials

https://www.coltonconsortium.org/publications/safety-and-efficacy-of-evobrutinib-in-relapsing-multiple-sclerosis-evolutionrms1-and-evolutionrms2-two-multicentre-randomised-double-blind-active-controlled-phase-3-trials/

Safety and tolerability of conversion to siponimod from other disease-modifying therapies in patients with advancing forms of relapsing MS: Results from the EXCHANGE study

https://www.coltonconsortium.org/publications/safety-and-tolerability-of-conversion-to-siponimod-from-other-disease-modifying-therapies-in-patients-with-advancing-forms-of-relapsing-ms-results-from-the-exchange-study/

Sclerotic GVHD and scleroderma share dysregulated gene expression that is ameliorated by EREG therapeutic antibody

https://www.coltonconsortium.org/publications/sclerotic-gvhd-and-scleroderma-share-dysregulated-gene-expression-that-is-ameliorated-by-ereg-therapeutic-antibody/

Short- and long-term effects of early versus delayed treatment with ocrelizumab on cerebellar volume loss in patients with RMS and PPMS

https://www.coltonconsortium.org/publications/short-and-long-term-effects-of-early-versus-delayed-treatment-with-ocrelizumab-on-cerebellar-volume-loss-in-patients-with-rms-and-ppms/

Spatial atlas of diabetic kidney disease reveals a B cell-rich subgroup

https://www.coltonconsortium.org/publications/spatial-atlas-of-diabetic-kidney-disease-reveals-a-b-cell-rich-subgroup/

Structural insights reveal interplay between LAG-3 homodimerization, ligand binding, and function

https://www.coltonconsortium.org/publications/structural-insights-reveal-interplay-between-lag-3-homodimerization-ligand-binding-and-function/